I. Excellent Immune Protection

1. Using the mammalian cell (CHO) expression system, the vaccine accurately mimics the native structure of the classical swine fever virus E2 protein, eliciting a strong humoral immune response with a single-dose immune protection rate of ≥95%.

2. Antibody titers are significantly enhanced, and the protection duration lasts more than 6 months, enabling “one-shot protection to slaughter”, reducing vaccination frequency and lowering labor and management costs.

3. The vaccine effectively blocks both vertical and horizontal transmission of the virus after immunization.

II. Industry-Leading Safety

1. Proprietary intelligent dual‑membrane i‑DuFil purification technology thoroughly removes impurities, ensuring vaccine purity and zero risk.

2. No viral nucleic acid residues, eliminating the risk of virulence reversion; serum‑free suspension culture completely avoids contamination risks from exogenous viruses such as BVDV.

3. Clinically validated to cause no immune stress reactions, ensuring stable and healthy swine herds.

III. Significant Economic Benefits

1. Long‑lasting protection with a single injection greatly reduces vaccination frequency and lowers overall costs for vaccines, labor and management.

2. Effectively controls the threat of wild virus latent infection, improves survival rate and production performance of swine herds, and directly increases farming profitability.

IV. Outstanding Purification Capability

1. Features DIVA technology (Differentiating Infected from Vaccinated Animals), enabling accurate identification of wild virus infection to support CSF eradication on swine farms.

2. Antibody levels are not interfered with by immunosuppressive diseases such as PRRS, ensuring consistent and reliable protection.